Ventripoint's AI-Powered Cardiac Imaging System VMS+ 4.0 Submitted for Expedited Regulatory Approval in China
核心洞察
Ventripoint Diagnostics (搜索)' strategic partner Lishman Global (搜索) has submitted the VMS+ 4.0 (搜索) AI-powered cardiac imaging system to China's NMPA for regulatory approval, qualifying for the expedited "green channel" review pathway.
The technology addresses China's massive cardiovascular disease burden affecting 330 million patients by providing MRI-equivalent volumetric measurements using standard 2D echocardiography through proprietary Knowledge Based Reconstruction technology.
VMS+ 4.0 (搜索) enables clinicians to assess all four heart chambers with high accuracy, supporting diagnosis and management of conditions including congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
Ventripoint Diagnostics (搜索) Ltd. has achieved a significant regulatory milestone as its strategic partner Lishman Global (搜索) Inc. formally submitted the company's VMS+ 4.0 (搜索) AI-powered cardiac imaging system to China's National Medical Products Administration (NMPA) for regulatory approval. The submission has qualified for the NMPA's "green channel" pathway, an expedited review process designed to accelerate approval of innovative medical technologies addressing significant clinical needs.
Addressing China's Cardiovascular Disease Crisis
The regulatory submission targets China's substantial cardiovascular disease burden, where the condition remains the leading cause of mortality affecting an estimated 330 million patients. Echocardiography serves as the most widely used cardiac imaging modality in China due to its cost-effectiveness, portability, and scalability across urban and rural healthcare settings. However, variability in image interpretation and limited access to advanced imaging modalities such as MRI have created a strong need for AI-driven diagnostic tools.
Revolutionary Cardiac Imaging Technology
VMS+ 4.0 (搜索) addresses these clinical gaps by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. The system is powered by Ventripoint's proprietary Knowledge Based Reconstruction technology, developed over a decade, which enables clinicians to assess all four chambers of the heart with high accuracy. The platform supports diagnosis and management of multiple cardiovascular conditions including congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
The technology's versatility allows integration with all ultrasound systems from any vendor and is already supported by regulatory market approvals in the U.S., Europe, and Canada.
Strategic Market Entry
"We are excited to take this important step toward bringing VMS+ 4.0 (搜索) to the Chinese market," said Paul Gibson, Chief Technology Officer of Lishman Global (搜索) Inc. "Qualification for the NMPA's green channel underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption. China's scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology."
Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics (搜索), emphasized the strategic importance of this milestone: "Hitting this regulatory milestone with Lishman Global (搜索) is a key validation of both our technology and our international strategy. China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 (搜索) to clinicians and patients more quickly."
Expanding Access to High-Quality Cardiac Care
The VMS+ 4.0 (搜索) system represents an affordable, gold-standard alternative that allows cardiologists greater confidence in patient management. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, the technology has the potential to significantly expand access to high-quality cardiac care across China's diverse healthcare landscape.
Lishman Global (搜索), established in 2012, specializes in assisting companies to safely enter the Chinese market through its partnership model, helping foreign companies navigate the complex network of regulatory approvals and multi-level distribution channels common in the Chinese medical device market.
The company will provide further updates as the regulatory review process progresses through the NMPA's expedited pathway.